Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678689 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
A Phase 2 study of Batten Disease and Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT02678689 is a Phase 2 study of Batten Disease and Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 14 participants, below the 2,828-participant average among 11 other Batten Disease trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02678689, a Phase 2 study of Batten Disease and Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treated with BMN 190 compared to natural history data from untreated historical controls.
Conditions Studied
Interventions
- BIOLOGICAL BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)
- DEVICE Intracerebroventricular access device
Study Locations (4)
Other
- Universitaetsklinikum Hamburg-Eppendorf - Hamburg
- Great Ormond Street Childrens Hospital - London
Ohio
- Nationwide Children's Hospital - Columbus
Piazza
- Children's Hospital Bambino Gesù,IRCCS - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-01-22 |
| Est. Completion | 2022-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02678689
The ClinicalTrials.gov registry entry for NCT02678689 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,828-participant average among 11 other Batten Disease trials with a reported enrollment target (100% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Batten Disease appearing as the primary indexed condition, and to 2 interventions - of which BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) is the first listed.
NCT02678689 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Ohio, Piazza.
Frequently Asked Questions
What is clinical trial NCT02678689 about?
NCT02678689 is a clinical study titled "A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease". This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treate...
What is the current status of trial NCT02678689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-01-22. Estimated completion is 2022-04-20.
What conditions does trial NCT02678689 study?
This clinical trial studies the following conditions: Batten Disease, Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2, Jansky-Bielschowsky Disease, CLN2 Disease, CLN2 Disorder.
What interventions are being tested in trial NCT02678689?
The interventions under investigation include: BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) (BIOLOGICAL), Intracerebroventricular access device (DEVICE).
Who is sponsoring clinical trial NCT02678689?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02678689 being conducted?
This trial has 4 study locations across Ohio, Piazza. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Batten Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Clinical and Neuropsychological Investigations in Batten Disease
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.